Prevalence of ESBLs in *Acinetobacter baumannii* isolated from intensive care unit (ICU) of Ghaem hospital, Mashhad, Iran

Elham Zarifi¹, Gilda Eslami²,³, Azad Khaledi⁴, Mahmood Vakili⁵, Hossein Vazini⁶ and Hengameh Zandi¹,²*

¹Department of Microbiology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.  
²Research Center for Food Hygiene and Safety, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.  
³Department of Parasitology and Mycology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.  
⁴Department of Microbiology and Immunology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.  
⁵Department of Community Medicine, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.  
⁶Nursing Department Basic Sciences Faculty, Hamedan Branch, Islamic Azad University, Hamedan, Iran.

http://dx.doi.org/10.22207/JPAM.11.2.20

(Received: 06 May 2017; accepted: 04 June 2017)

*Acinetobacter baumannii* is an important opportunistic pathogen that mainly infects critically patients in intensive care units (ICU). The production of plasmid-mediated extended-spectrum β-lactamases (ESBLs) is one of the most important mechanisms of resistance against β-lactam antibiotics. This study aimed to evaluate the prevalence of ESBLs in *A. baumannii* isolated from ICU of Ghaem hospital, Mashhad, Iran. A total of 140 *A. baumannii* isolates recovered from hospitalized patients in ICU of Ghaem hospital in Mashhad city from December 2014 to March 2015. Identification of *A. baumannii* isolates carried out using biochemical laboratory methods and then confirmed by OXA-51 PCR screening. Susceptibility testing performed using disk diffusion (Kirby-Bauer) method as recommended by CLSI guidelines. *A. baumannii* isolates screened for production of ESBLs using combination disk test. blaPER, blaGES, blaTEM, blaSHV, blaCTX, blaVEB and blaOXA-10 beta-lactamase genes detected using conventional PCR. The most antibacterial resistance was against cefuroxime (99.3%) and colistin was the most effective antibiotic. None of the isolates were ESBL producer by combination disk test. However, results of PCR revealed that the prevalence of blaPER, blaGES and blaTEM genes were 7.1%, 4.3% and 27.1%, respectively, blaCTX, blaVEB, and blaOXA-10 were not found in any of isolates. According to the results, the high resistance was seen against selected antibiotics and the phenotypic tests are not sufficient alone for determination of ESBLs producer of *A. baumannii* isolates. So, molecular tests are also necessary for detection of these enzymes.

Keywords: *A. baumannii*, ESBLs, ICU, Iran.

Bacteria which constitute the *Acinetobacter* genus were originally identified in the first decade of the 20th century. *Acinetobacter* is a genus of gram-negative bacteria belonging to the gammaproteobacterial. *Acinetobacter* are rod-shape during rapid growth and coco-bacillary in the stationary phase. They are generally encapsulated, nonmotile, aerobic, gram-negative organisms with tendency to retain crystal violet and therefore to be incorrectly identified as gram-positive cocci.
Frequent misidentification of *Acinetobacter* as *Neisseria* or *Moraxella* on gram staining is readily clarified by the negative oxidase reaction of *Acinetobacter*. Additionally, *Acinetobacter* are catalase-positive. Hemolysis of red blood cells, acidification of glucose, growth at 44°C, and variability in carbon source uptake are few of the phenotypic characteristics applied to distinguish *Acinetobacter* strains. *A. baumannii* isolates are more likely caused disease in patients with immunosuppression, serious underlying disease and people who are exposed to invasive procedures accompanying treatment with broad-spectrum antibiotics. Therefore, the spread of these species in ICU and burn wards is more. *A. baumannii* is an important cause of nosocomial infection, such as ventilator associated pneumonia (VAP), urinary tract infections, wound infections, and septicemia. *A. baumannii* is a significant opportunistic pathogen that mainly infects critically ill patients in ICU.

As known the ability of *A. baumannii* to achieve different mechanisms of resistance, also, resistance to all available common antibiotics as well as lack of new effective antimicrobial drugs are the most important causes of risk about this organism. *A. baumannii* isolates which are resistant to three or more classes of antibiotics are called multi-drug resistant strains (MDR). Increasing antibiotic resistance in *Acinetobacter* inhibits from appropriate management in antibiotic therapy.

*A. baumannii* has several innate resistance mechanisms to a number of antibiotics, such as aminopenicillins, first-and second- generation cephalosporins and chloramphenicol. Besides this, it has a considerable capacity to acquire mechanisms conferring resistance to broad-spectrum β-lactams, carbapenems, aminoglycosides and fluoroquinolones. Beta lactam antibiotics (mainly carbapenems) are now the first drug of choice to treat this microorganism; however, in the last decade, resistance to carbapenems has appeared in hospitals worldwide owing to the production of beta-lactamase, change in permeability, increase in efflux, and modification of the affinity of penicillin-binding proteins (PBP2) in these bacteria. Production of plasmid-mediated extended-spectrum β-lactamases (ESBLs) is one of the most important mechanisms of resistance against beta-lactam antibiotics. Many of these enzymes have evolved from TEM and SHV -lactamases, but recently a large number of ESBLs are related to TEM and SHV, such as GES and VEB, have been described. Plasmid is accounted for distribution of the most beta lactamases; however, the gene encoding these enzymes may also be on the chromosome or transposable elements and integrons.

ESBLs are also able to hydrolyze three and four generation cephalosporins and monobactams. ESBLs producer isolates are inhibited by β-lactamase inhibitors (clavulanic acid, sulbactam and tazobactam). At present, there are more than 300 different ESBL variants, and these have been clustered into nine different structures and these evolutionary families based on amino acid sequence. TEM, CTX, SHV, GES, VEB, OXA-10 and PER are the major types.

In according to the information on the prevalence of these enzymes and antibacterial resistance pattern, control, prevention and treatment of this bacterium is important, thus, this study aimed to evaluate the prevalence of ESBLs in *A. baumannii* isolated from ICU of Ghaem hospital, Mashhad, Iran.

**MATERIALS AND METHODS**

**Bacterial sources**

A total of 140 *A. baumannii* isolates were recovered from hospitalized patients in ICU of Ghaem hospital in Mashhad city from December 2014 to March 2015. All nonlactose fermenting members were subjected to microbiologic and biochemical tests such as; gram staining, oxidase, catalase, O/F, and growth at 42 °C on nutrient agar medium. For confirmation of *A. baumannii* isolates, API20NE kit (version 6.0, bio-Merieux, Marcy L’Etoile, France) was applied. Then until use, clinical isolates were stored in nutrient broth containing 20% glycerol at -80 °C.

**Antibiotic Susceptibility Testing**

Antibiotic Susceptibility Testing performed using modified Kirby-Bauer disk diffusion method based on CLSI guidelines. The potency of antibiotics disks was checked by reference strains *Pseudomonas aeruginosa* ATCC 27853. After incubation for a period of 24 h, results were reported as sensitive, intermediate, or resistant according to the zone diameters. The antibiotics...
used were imipenem (10 µg), meropenem (10 µg), colistin (25 µg), amikacin (30 µg), ceftazidime (30 µg), cefotaxime (30 µg), ceftriaxone (30 µg), ceftazidime (30 µg), ceferpine (30 µg), ertapenem (10 µg) and ampicillin/sulbactam (10 µg).

**Phenotypic Detection of Beta-Lactamase**

In phenotypic confirmation of ESBLs producers on Muller Hinton agar, the combination disc test (CDT) was applied as previously defined. Cefotaxime (30 µ) or ceftazidime disks (30 µ) with or without clavulanate (10 µ) were used. After incubation of plates for 24 h at 37 °C, if the diameter of inhibition zone for each of these antibiotics in combination with clavulanic acid compared to antibiotics alone, increased by more than 5 mm, they defined as the ESBL-producing isolates, if no, isolates were reported as ESBL negative. *P. aeruginosa* ATCC 27853 was applied for quality control of isolates.

**DNA extraction and PCR**

For DNA extraction and template preparation, the boiling method was used as previously described and lastly samples stored at -20 °C, till use. The primer pair sequences designed by primer premier software for detection of ESBL genes in clinical isolates of *A. baumannii* using PCR technique are shown in Table 1. Of note, PCR of *bla* _OXA-51_*-like gene was also used for confirmation of isolates identification. The PCR program for *bla* _GES_, *bla* _CTX_ and *bla* _PER_ genes was composed of an initial denaturation step (94 °C, 5 min) followed by 30 cycles of denaturation step (94 °C, 1 min), annealing step (60 °C, 1 min), and extension step (72 °C, 1 min) with final extension (72 °C, 7 min). The DNA amplification program for *bla* _shv*, *bla* _SHV_ *bla* _veb_ and *bla* _TEM_ genes was similar to previous genes except that the annealing temperature was 51 °C. Components of PCR master mix (Amplicon, Denmark) were as follows; 1.5 mM MgCl₂, 10 pmol/µl of each primer, 0.2 mM dNTPs, 1U Taq DNA polymerase, 1X PCR buffer and 50 ng/µl DNA. PCR products were analyzed using 2% agarose gel electrophoresis (Cinaagen, IRAN). And 50bp DNA ladder (Fermentas company product) was used to detect the specific PCR products related to the bla genes. Then, results were observed under UV light gel documentation system.

**Sequencing of PCR products**

The PCR products of three samples for each mentioned gene were subjected to direct sequencing and the nucleotide sequences were evaluated and analyzed with CLUSTAL W2 and BLAST softwares.

**Data analysis**

SPSS software (version 22, Chicago, IL, USA) was used for performing the statistical analysis using chi-squire and Fisher’s exact tests. Also, P-value<0.05 was considered as significant statistically.

**RESULTS**

In this study, a total of 140 isolates *A. baumannii* collected from ICU of Ghaem hospital in Mashhad, Iran, from December 2014 to March

<table>
<thead>
<tr>
<th>Primer Name</th>
<th>5′- primer sequence - 3′</th>
<th>Size, bp</th>
</tr>
</thead>
<tbody>
<tr>
<td>F- GES</td>
<td>CGCTTCATTCCAGCCTATTACTG</td>
<td>682</td>
</tr>
<tr>
<td>R- GES</td>
<td>TCTTCACCACACCACTCTTATTAGG</td>
<td>547</td>
</tr>
<tr>
<td>F- VEB</td>
<td>GCCAGAATAGGAGTAGCAAT</td>
<td>271</td>
</tr>
<tr>
<td>R- VEB</td>
<td>GGTACTTCTCTTGTGGTTT</td>
<td>378</td>
</tr>
<tr>
<td>F- TEM</td>
<td>CAGTGCTGCCAAACTCAT</td>
<td>165</td>
</tr>
<tr>
<td>R- TEM</td>
<td>CGCCTCCACAACTCTCTTAT</td>
<td>461</td>
</tr>
<tr>
<td>F- SHV</td>
<td>GCGGCACCTGAATATCTA</td>
<td>349</td>
</tr>
<tr>
<td>R- SHV</td>
<td>TCTTAGCCGCTAGCTGGTAATTAG</td>
<td>118</td>
</tr>
<tr>
<td>F- OXA</td>
<td>TCTTAGCCGCTAGCTGGTAATTAG</td>
<td>378</td>
</tr>
<tr>
<td>R- OXA</td>
<td>ATATCGTGGTGGTGGCATTAATCTC</td>
<td>461</td>
</tr>
</tbody>
</table>

Table 1. Primer sequences of ESBL genes amplified by PCR.
2015. The sources of isolates were as follows; Trashes 71 (50.7%), Urine 50 (35.7%), Wound 10 (7.2%) and Blood Culture 9 (6.4%). Overall, 51.4%, 48.6% of the hospitalized patients were female and male, respectively. The most frequent isolates of *A. baumannii* (with prevalence of 40%) were in the age group 31-50 years. Also, the most rates of isolates (with prevalence of 51.4%) were seen in female than male.

As shown in Table 2, results of antibacterial susceptibility pattern revealed that in *A. baumannii* the high resistance was to all antibiotics except colistin, as resistance rates to imipenem, meropenem, cefazidime, cefotaxime, cefuroxime, ceftriaxone, Cefepime, ertapenem and ampicillin/sulbactam were 97.9%, 98.1%, 96.4%, 97.9%, 99.3%, 97.9%, 97.9%,98.6% and 97.1%, respectively. The most effective antibiotic against *A. baumannii* was colistin with susceptibility 97.9% followed by amikacin with sensitivity 27.1% (Table 2).

It was also presented that none of the isolates were ESBL producers by Combination disk method. Although *A. baumannii* isolates exhibited a high degree of resistance to third-generation cephalosporins but they did not produce ESBL.

PCR revealed that the prevalence of *blaPER, blaGES, blaTEM* genes were 7.1%, 4.3% and 27.1%, respectively. *blaCTX, blaVEB*, and *blaOXA-10* were not found in any of isolates (Table 3 and Figures 1-3).

*A. baumannii* isolates which at one time had two ESBL genes were: *blaPER/blaGES* 2(1.4%),

### Table 2. Antimicrobial susceptibility pattern of *A. baumannii* isolates

<table>
<thead>
<tr>
<th>Antimicrobials</th>
<th>Resistance, No. (%)</th>
<th>Intermediate, No. (%)</th>
<th>Sensitivity, No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>imipenem</td>
<td>137 (97.9)</td>
<td>0</td>
<td>3 (2.1)</td>
</tr>
<tr>
<td>meropenem</td>
<td>138 (98.6)</td>
<td>0</td>
<td>2 (1.4)</td>
</tr>
<tr>
<td>colistin</td>
<td>3 (2.1)</td>
<td>0</td>
<td>137 (97.9)</td>
</tr>
<tr>
<td>amikacin</td>
<td>94 (67.1)</td>
<td>8 (5.7)</td>
<td>38 (27.1)</td>
</tr>
<tr>
<td>cefazidime</td>
<td>135 (96.4)</td>
<td>0</td>
<td>5 (3.6)</td>
</tr>
<tr>
<td>cefotaxime</td>
<td>137 (97.9)</td>
<td>1 (0.7)</td>
<td>2 (1.4)</td>
</tr>
<tr>
<td>cefuroxime</td>
<td>139 (99.3)</td>
<td>0</td>
<td>1 (0.7)</td>
</tr>
<tr>
<td>ceftriaxone</td>
<td>137 (97.9)</td>
<td>1 (0.7)</td>
<td>2 (1.4)</td>
</tr>
<tr>
<td>cefepime</td>
<td>137 (97.9)</td>
<td>0</td>
<td>3 (2.1)</td>
</tr>
<tr>
<td>ertapenem</td>
<td>138 (98.6)</td>
<td>0</td>
<td>2 (1.4)</td>
</tr>
<tr>
<td>ampicillin/sulbactam</td>
<td>136 (97.1)</td>
<td>2 (1.4)</td>
<td>2 (1.4)</td>
</tr>
</tbody>
</table>

### Table 3. Frequency distribution of ESBLs genes in clinical *A. baumannii* isolates

<table>
<thead>
<tr>
<th>Genes</th>
<th>Number</th>
<th>Genes</th>
<th>Number (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>blaTEM</em></td>
<td>38(27.1%)</td>
<td><em>blaCTX</em></td>
<td>000</td>
</tr>
<tr>
<td><em>blaSHV</em></td>
<td>9(6.4%)</td>
<td><em>blaGES</em></td>
<td>6(4.2%)</td>
</tr>
<tr>
<td><em>blaPER</em></td>
<td>10(7.1%)</td>
<td><em>blaOXA-10</em></td>
<td>000</td>
</tr>
<tr>
<td><em>blaGES</em></td>
<td>6(4.2%)</td>
<td><em>blaVEB</em></td>
<td>000</td>
</tr>
</tbody>
</table>

### Table 4. Frequency distribution of ESBLs genes in *A. baumannii* isolates based on types of clinical samples

<table>
<thead>
<tr>
<th>Genes</th>
<th>Trashes, N=71</th>
<th>Urine, N=50</th>
<th>Wound, N=10</th>
<th>Blood culture, N=9</th>
<th>P- value</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>blaTEM</em></td>
<td>18(25.4%)</td>
<td>15(30%)</td>
<td>2(20%)</td>
<td>3(33.3%)</td>
<td>0.86</td>
</tr>
<tr>
<td><em>blaSHV</em></td>
<td>5(7%)</td>
<td>3(6%)</td>
<td>0</td>
<td>1(11.1%)</td>
<td>0.78</td>
</tr>
<tr>
<td><em>blaPER</em></td>
<td>3(4.2%)</td>
<td>6(12%)</td>
<td>1(10%)</td>
<td>0</td>
<td>0.32</td>
</tr>
<tr>
<td><em>blaGES</em></td>
<td>2(2.8%)</td>
<td>4(8%)</td>
<td>0</td>
<td>0</td>
<td>0.40</td>
</tr>
<tr>
<td><em>blaCTX</em></td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0.00</td>
</tr>
<tr>
<td><em>blaOXA-10</em></td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0.00</td>
</tr>
<tr>
<td><em>blaVEB</em></td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0.00</td>
</tr>
</tbody>
</table>
ZARIFI et al.: PREVALENCE OF ESBLs IN A. baumannii

blα_{SHV}/blα_{GES} 2(1.4%), blα_{SHV}/blα_{TEM} 2(1.4%),
blα_{GES}/blα_{TEM} 1(0.7%).

In addition, results showed that there
no correlation was found between prevalence
of ESBLs genes and types of clinical samples
(p>0.05), as per Table 4.

DISCUSSION

A. baumannii is mostly found in hospital
settings and is nowadays noticed more than ever
due to its survival ability in such environments and
causing nosocomial infections. In this study, among
the aminoglycosides, amikacin was resistant in
67.1% of cases and in other groups; cephalosporins,
carbapenems, and penicillin were almost 100%
resistant, indicating multiple drug resistance in
these isolates. Colistin was the most effective
antibiotic (97.9%). Our results demonstrated that
the rate of resistance was significantly lower in
colistin compared to other antibiotics. The possibly
reason for low resistance to this antibiotic may
be owing to its infrequent prescription during the
recent period. In a study conducted by Shahcheraghi
et al (2009) on A. baumannii isolated from patients
hospitalized in Tehran hospitals showed a large
proportion of isolates were resistant to ceftriaxone
(96.8%), cefotaxime (95.7%), ceftazidime (78.9%),
amd cefepime (100%), while 95.8% of isolates were
susceptible to colistin, which their findings were
consistent with current study. This study, like the
studies carried out by Tseng et al in China in 2007
13 and Smolyakov et al in 200014, confirmed that
most isolates were resistant to ceftazidime and
defepime. Regarding the present results and similar
studies, due to over-administration of the third
generation cephalosporins and lack of observing
the hygienic principles in the community, a
considerable resistance has been developed against this generation of cephalosporins. So, based these findings, the third generation cephalosporins are not good choice for treatment of infections caused by MDR A. baumannii isolates.

The study conducted by Srinivasan and colleagues in Ohio, USA15, more than 80% of the isolates were resistant to a wide range of cephalosporins and 20% to imipenem, while in our study, resistance to imipenem was more than 90%, which this dissimilarity might be due to unnecessary overuse of antibiotics. An another study conducted by Akan et al in 2002, in Turkey on 277 A. baumannii isolates revealed that the resistance rate to imipenem and amikacin was 53.6% and 59.8%, respectively16, in contrast, this rate was much higher in our study and also in comparable above mentioned ones. All of studies stated here used disk diffusion agar method to evaluate antibiotic susceptibility similar to our study. Therefore, the difference in results could be attributed to diversity in types of isolates, variety in antibiotic disks used, and difference in geographical regions of the studies and policies of infection control17. Thus, the regional determination of antibiotic susceptibility of A. baumannii can act as a suitable guide for effective use of routine antibiotics. Since in this study and similar ones, the most A. baumannii isolates (50.7%) were obtained from pulmonary secretions, it appears that the respiratory tract is the most involved in infections caused by A. baumannii. So, disinfection and sterilization of equipment and respiratory devices like respiratory is one of the ways for prevention of infection dissemination. Based on the studies conducted in our country (Iran) and through study reported by Sharif et al in 2013, 51% of A. baumannii isolates had the wide-range beta-lactamase-producing phenotype18. Also, Owlia et al in 2012, in Tehran reported that 21% of A. baumannii isolates had the wide-range beta-lactamase-producing phenotype19. Similarly, this rate was reported 28% in a study conducted by Sinha et al in India in 20078. Shakibaie et al in 2012 identified only 3 ESBL-producing among 100 A. baumannii isolates20. The study by Jazani et al (2010) reported only 1 ESBL-producing isolate from among 48 A. baumannii isolates recovered from clinical samples of patients hospitalized in burn hospital, Tehran21. In present study, we used the combination disk method similar to the method used in the mentioned studies, there was no positive test regarding phenotype. One probable reason for lack of production of extended β-lactamase-producing phenotype in the present study, compared to other studies, may be increased expression of AmpC genes and also beta-lactamases and metallo beta-lactamase enzymes. It is also possible that mechanisms other than extended β-lactamase like secretory pumps and variations in porins induce resistance in this organism. Indeed, resistance in A. baumannii is associated with a combination of various mechanisms including acquisition of β-lactamases, stable induction of AmpC, reduced permeability, changes in penicillin binding proteins, and somewhat, with an increase in Efflux pumps21. Performing of phenotypic tests alone is not able to determine the ESBL-producing isolates in A. baumannii. Some molecular tests need be performed to determine the presence of ESBL enzymes.

The blaOXA-51 gene is considered as a chromosol component of A. baumannii isolates which can used to identify this organism,22 for this reason in present study we used blaOXA-51 gene for confirmation of the A. baumannii isolates.

Azhari and et al in 2010 in Tabriz indicated that among 100 isolates of A. baumannii from different clinical samples, PER gene was not found in any of samples23. The first report of presence of PER gene was detected in a study conducted by Farajnia and et al in 2013 in Tabriz, wherein its prevalence was 51.7%24, which was higher than over results. But another in 2007 in Argentina presented that among 1 out of 6 isolates was positive for PER gene25.

Shahcheraghi et al in 2009 in Tehran revealed that of 95 isolates, 12.8% were reported positive for TEM26 while this rate in study carried out by Sharif and et al in 2012 in Tehran was 56%18. In another one in America in 2010, occurrence of TEM was 37%27, which is partly in line with present study.

GES was first reported in the study by Shahcheraghi et al in 2011 in Tehran, Iran, in which 2 out of 100 A. baumannii isolates were resistant to imipenem28. Furthermore, in the study carried out by Bogaerts et al in 2009 in Belgium, 9 out of 125 isolates were reported positive for GES gene which is relatively similar to our study with
6 positive isolates\textsuperscript{28}. Also VEB was first reported in the study performed by Poirel et al in 2003 in France, in which 7 cases (58.3\%) out of 12 \textit{A. baumannii} isolates were positive for VEB gene\textsuperscript{29}. In the study conducted by Pasteran and colleagues in 2006 in USA, 47.6\% of isolates possessed the VEB gene\textsuperscript{30}. Moreover, in the study carried out by Farajnia et al in 2009 in Tabriz, Iran, 10\% out of 100 \textit{A. baumannii} isolates were reported positive for VEB gene\textsuperscript{24}, in contrast none of isolates were positive for VEB gene in our study.

Vafaei and et al presented of 130 \textit{A. baumannii} isolates, 19\% of those were positive for CTX gene\textsuperscript{31}. But in the study conducted by Ramoul and colleagues in 2013, CTX was not found in any of the isolates\textsuperscript{32}, which is close to our results.

Several studies suggested varying distribution of resistant genes in different geographical regions. Geographical distance and also pattern of antibiotic usage can predispose to emergence of resistant genes in different geographical areas. As Beta-lactamase-producing isolates constitute a lower percentage compared to Beta-lactam-resistant isolates, it seems that in addition to the production of Beta-lactamases, other factors like the presence of Efflux pumps and cellular wall canals or purines also contribute to the creation of resistance. Due to the capacity of these isolates for transmitting resistance genes to other clinical isolates, the exact identification of Beta-lactamases genes contributing resistance is of most importance for care, treatment, and epidemiologic studies on transmission methods in hospitals\textsuperscript{33}.

The high resistance of isolates to third and fourth generation of cephalosporins compared to the low number of ESBL producing isolates, proposed another resistance mechanisms such as secretory pump, purines, biofilm information involved in development of resistance.

Hence, the development in policies of antibiotic prescription and infection control are more critical to prevent the spreading of such resistant infectious organisms.

**CONCLUSION**

According to the results, the high resistance was seen against selected antibiotics and the phenotypic tests are not sufficient alone for determination of ESBLs producer of \textit{A. baumannii} isolates. So, molecular tests are also necessary for detection of these enzymes.

**ACKNOWLEDGEMENTS**

We would like thank our colleagues in Laboratory of Medical Microbiology of Ghaem hospital for Clinical Samples Collection.

**REFERENCES**

7. K. M. Hujer et al., “Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center,” \textit{Antimicrobial agents and chemotherapy}, 2006; 50(12): pp. 4114-4123.
10. M. Moghadamshakib et al., “ISSN 0975-413X CODEN (USA): PCHHAX.”
30. F. Pasterán et al., “Emergence of PER-2 and VEB-1a in Acinetobacter baumannii strains...

